Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H26N2O4S |
Molecular Weight | 378.486 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)CCC[C@H](NC(=O)[C@@H](S)CC2=CC=CC=C2)C(=O)N1CC(O)=O
InChI
InChIKey=YRSVDSQRGBYVIY-GJZGRUSLSA-N
InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1
Molecular Formula | C19H26N2O4S |
Molecular Weight | 378.486 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:35:29 UTC 2023
by
admin
on
Fri Dec 15 15:35:29 UTC 2023
|
Record UNII |
MU9089C77W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
||
|
NCI_THESAURUS |
C783
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C99557
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
300000034217
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
CHEMBL107747
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
MU9089C77W
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
9886079
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
LL-99
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
160135-92-2
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
GEMOPATRILAT
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
8055
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY | |||
|
DTXSID901029484
Created by
admin on Fri Dec 15 15:35:29 UTC 2023 , Edited by admin on Fri Dec 15 15:35:29 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
EXCRETED UNCHANGED |
No gemopatrilat was detected in urine and feces.
FECAL; URINE
|
||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
Term
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
Metabolites M9 and M10, which were not well resolved, accounted for 8% of the radioactivity
PLASMA
|
||
|
METABOLITE -> PARENT |
The prominent metabolites in the 1-h human plasma before DTT reduction were M2, M13, and M14, which together accounted for 31% of the radioactivity.
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
FECAL
|
||
|
METABOLITE -> PARENT |
FECAL; URINE
|
||
|
METABOLITE -> PARENT |
Metabolites M9 and M10, which were not well resolved, accounted for 8% of the radioactivity
PLASMA
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
P.O. ADMINISTRATION |
|
||
Tmax | PHARMACOKINETIC |
|
P.O. DMINISTRATION |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||